Pharmacological Agents for the Treatment of Adult Attention Deficit Hyperactivity Disorder: A Review of the Literature

Abstract

Adult attention deficit hyperactivity disorder (ADHD) has been an emerging area of psychiatry of particular interest over the past few years. Whether this attention is due to new medications prompting the issue (ie, Focalin^TM, Strattera^TM) or emerging awareness that an estimated 4.4% of adults suffer with this diagnosis, therapy is of a limited selection. Untreated symptoms can lead to several life problems, including work and school difficulties, personal relationship issues, low self-esteem, and an increased chance of tobacco use, alcohol abuse, or other substance abuse. This article is to serve as a general overview of the available information regarding adult ADHD and the pharmacologic therapies available to treat the disorder.

Keywords

Adult ADHD alpha-2 agonists antidepressants atomoxetine stimulants.

Get full access to this article

View all access options for this article.

References

Faraone SV , Spencer TJ , Montano B. , et al. Attention-deficit/ hyperactivity disorder in adults: a survey of current practice in psychiatry and primary care . Arch Intern Med. 2004; 164(11): 1221-1226 .

Okie S. ADHD in adults . N Eng J Med. 2006;354(25): 2637-2641 .

Kessler RC , Adler L. , Barkley R. , et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey replication . Am J Psychiatry. 2006;163(4): 716-723 .

Biederman J. Pharmacotherapy for attention deficit hyperactivity disorder (ADHD) decreases the risk for substance abuse: findings from a longitudinal follow-up of youths with and without ADHD . J Clin Psychiatry. 2003;64(S11): 3-8 .

Faraone SV , Spencer T. , Aleardi M. , et al. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/ hyperactivity disorder . J Clin Psychopharmacol . 2004;24(1): 24-29 .

Clark L. , Blackwell AD , Aron Ar , et al. Association between response inhibition and working memory in adult ADHD: a link to right frontal cortex pathology ? Biol Psychiatry. 2006; in press.

Wilens TE , Faraone SV , Biederman J. Attention-deficit/ hyperactivity disorder in adults . JAMA. 2004;292(5): 619-623 .

FDA Center for Drug Evaluation and Research. Alert for healthcare professionals—pemoline tablets and chewable tablets (marketed as CYLERT); FDA Alert [10/2005]: Liver injury risk and market withdrawal . Medical Review [Online]. Available at: http://www.fda.gov. Accessed October 23, 2006.

Bender L. , Cottington F. The use of amphetamine sulfate (Benzedrine) in child psychiatry . Am J Psychiatry. 1942;99(1): 16-121 .

10.

Laufer M. , Denhoff E. , Solomons G. Hyperkinetic impulse disorder in children's behavior problems . Psychosom Med. 1957; 19(1): 38-49 .

11.

Greenhill LL , Pliszka S. , Dulcan Mk , et al. Summary of the practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults . J Am Acad Child Adolesc Psychiatry. 2001;40(11): 1352-1355 .

12.

Gibson AP , Bettinger TL , Patel NC , et al. Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder . Ann Pharmacother. 2006;40(6): 1134-1142 .

13.

Wigal S. , Swanson JW , Feifel D. , et al. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-thre-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder . J Am Acad Child Adolesc Psychiatry. 2004;43(11): 1406-1414 .

14.

Adis R&D Profile—dexmethylphenidate . Drugs R&D. 2002; 3(4): 279-282 .

15.

FocalinTM (dexmethylphenidate) package insert. Gainesville, Ga: Novartis Pharmaceuticals Corp; 2006.

16.

Mannheim GB Clinical review (NDA on SparlonTM). FDA Center for Drug Evaluation and Research. Available at: http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4212b1-01-02-FDA-Tab2.pdf . Accessed October 24, 2006.

17.

Simpson D. , Plosker GL Adis drug evaluation—atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder . Drugs. 2004;64(2): 205-222 .

18.

Adler L. , Dietrich A. , Reimherr FW , et al. Safety and tolerability of once versus twice daily atomoxetine in adults with ADHD . Ann Clin Psychiatry. 2006;18(2): 107-113 .

19.

Wernicke JF , Adler L. , Spencer T. , et al. Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment . J Clin Psychopharmacol. 2004;24(1): 30-35 .

20.

Caballero J. , Nahata MC Atomoxetine hydrochloride for the treatment of attention-deficit/hyperactivity disorder . Clin Ther. 2003;25(12): 3065-3083 .

21.

Turner DC , Clark L. , Dowson J. , et al. Modafinil improves cognition and response inhibition in adult attention-deficit/ hyperactivity disorder . Biol Psychiatry. 2004;55(10): 1031-1040 .

22.

Wilens TE , Biederman J. , Prince J. , et al. Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder . Am J Psychiatry. 1996;153 (9): 1147-1153 .

23.

Maidment ID The use of antidepressants to treat attention deficit hyperactivity disorder in adults . J Psychopharmacol . 2003;17(3): 332-336 .

24.

Higgins ES A comparative analysis of antidepressants and stimulants for the treatment of adults with attention-deficit hyperactivity disorder . J Fam Pract. 1999;48(1): 15-20 .

25.

Wilens TE , Spencer T. , Biederman J. , et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults . Am J Psychiatry. 2001;158(2): 282-288 .

26.

Kuperman S. , Perry PJ , Gaffney GR , et al. Bupropion SR versus methylphenidate versus placebo for attention deficit hyperactivity disorder in adults . Ann Clin Psychiatry. 2001; 13(3): 129-134 .

27.

Wender PH , Reimherr FW Bupropion treatment of attention-deficit hyperactivity disorder in adults . Am J Psychiatry. 1990;147(8): 1018-1020 .

28.

Upadhyaya HP , Brady KT , Sethuraman G. , et al. Venlafaxine treatment of patients with comorbid alcohol/cocaine abuse and attention-deficit hyperactivity disorder: a pilot study . J Clin Psychopharmacol . 2001 ;21(1): 116-118 .

29.

Hornig-Rohan M. , Amsterdam JD Venlafaxine versus stimulant therapy in patients with dual diagnosis ADD and depression . Prog Neuropsychopharmacol Biol Psychiatry. 2002;26(3): 585-589 .

30.

Hedges D. , Reimherr FW , Rogers A. , et al. An open trial of venlafaxine in adult patients with attention deficit hyperactivity disorder . Psychopharmacol Bull. 1995;31(4): 779-783 .

31.

Adler LA , Resnick S. , Kunz M. , et al. Open-label trial of venlafaxine in adults with attention deficit disorder . Psychopharmacol Bull. 1995;31(4): 785-788 .

32.

Findling RL , Schwartz MA , Flannerly DJ , et al. Venlafaxine in adults with attention-deficit/hyperactivity disorder: an open clinical trial . J Clin Psychiatry. 1996;57(5): 184-189 .

33.

Reimherr FW , Hedges DW , Strong RE An open trial of venlafaxine in adult patients with attention deficit hyperactivity disorder . Psychopharmacol Bull. 1995;31: 609 .

34.

Xu C. , Schachar R. , Tannock R. , et al. Linkage study of alpha-2a adrenergic receptor in attention-deficit hyperactivity disorder families . Am J Med Genet. 2001;105(2): 159-162 .

35.

Hunt RD , Arnsten AF , Asbell MD An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder . J Am Acad Child Adolesc Psychiatry . 1995;34(1): 50-54 .

36.

Taylor FB , Russo J. Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder . J Clin Psychopharmacol. 2001;21(2): 223-228 .